核酸检测质量监测指标评价与无效结果成因分析
徐州市红十字血液中心 2.徐州医科大学附属医院
目的 回顾性分析无偿献血者核酸检测(NAT)结果,评估NAT质量监测指标并探讨无效结果成因,为提升NAT检测质量提供科学依据。方法 收集2023年1月1日至2024年12月31日期间的201186例无偿献血者NAT的资料。计算NAT不合格率、NAT拆分反应率、NAT无效批次率和试剂使用率。同时和国家临床检验中心发布的数据进行比较和分析。结果 2023-2024年NAT不合格率均值为0.06%,各季度差异无统计学意义(P>0.05),且各季度均不高于全国同组试剂平均水平。NAT拆分反应率均值为47.20%,各季度差异无统计学意义(P>0.05),且有4个季度低于全国同组试剂平均水平。NAT无效批次率均值为2.14%,各季度差异无统计学意义(P>0.05),且有6个季度高于全国同组试剂平均水平。NAT试剂使用率均值为144.49%,各季度差异有统计学意义(P<0.05),且有6个季度高于全国同组试剂平均水平。设备故障和对照无效是NAT结果无效的两大主要原因,分别占NAT无效结果总数的46.52%和38.37%。结论 历年NAT质量指标趋势及全国数据对标表明,监测指标可反映核酸检测全过程、预警风险并优化质控体系;设备故障、对照失效造成结果无效,为实验室亟待解决的难题。
Objective To systematically evaluate nucleic acid testing(NAT) quality monitoring indicators and thoroughly investigate the causes of invalid results and provide a scientific basis for improving nucleic acid testing(NAT) testing quality by retrospectively analyzing NAT results from voluntary blood donors. Methods We collected data from 201,186 voluntary blood donors tested between January 1, 2023, and December 31, 2024 at the Xuzhou Red Cross Blood. We calculated the following parameters: NAT reactive rate, NAT resolution reactive rate, NAT invalid batch rate, and reagent utilization rate, and compared them with data published by the National Center for Clinical Laboratories. Results From 2023 to 2024, the average NAT reactive rate was 0.06%, with no statistically significant differences across quarters(P>0.05), and all quarterly NAT reactive rates were not higher than the national average for the same reagent group. The average NAT resolution reactive rate was 47.20%, showing no significant differences across quarters(P>0.05), and four quarters exhibited rates below the national average for the same reagent group. The average NAT invalid batch rate reached 2.14%, without statistically significant differences across quarters(P>0.05), and six quarters recorded rates higher than the national benchmark for the same reagent group. The average reagent utilization rate was 144.49%, demonstrating statistically significant differences across quarters(P<0.05), and six quarters exceeded the national average for the same reagent group. Equipment failure and invalid controls were the two primary reasons for NAT invalid results, accounting for 46.52% and 38.37% respectively. Conclusion The trend analysis of annual NAT quality indicators and comparison with national data show that monitoring indicators can reflect the whole process of nucleic acid testing, alert potential risks and optimize the quality control system. Invalid test results caused by equipment failures and failed controls remain urgent problems to be solved in laboratories.
引用本文
按标准格式复制,或导出到文献管理软件参考文献
共 7 条- [1]国家卫生健康委员会医政司.血站技术操作规程(2019版)[S].2019-04-28.
- [2]桂嵘,王勇军,周细国.医疗机构中乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒(1+2型)核酸检测策略专家共识[J].临床输血与检验,2020,22(6):561-564.
- [3]方建华,王艺芳,葛文超,等.核酸检测实验室质量监控指标的探讨[J].中国输血杂志,2019,32(4):399-402.
- [4]中国输血协会.血站血液检测实验室质量监测指标:T/CSBT 004-2019[S].
- [5]董珀,何亚琴,濮云峰.常州市中心血站HBV筛查中酶联免疫检测与核酸检测结果不一致的分析[J].临床与病理杂志,2020,40(6):1357-1362.
- [6]董菲,柳杨,董国良,等.血站核酸混检模式质量指标监测及应用评价[J].中国输血杂志,2025,38(2):251-256.
- [7]刘春兰,姜敏娜,宋雷.血站核酸检测实验室质量监测指标分析[J].国际检验医学杂志,2021,42(15):1902-1905.
| 文章编号 | 2026-04-042(期号内编号) |
|---|---|
| 栏目 | 检验与方法 |
| 作者 | 钱露1;张帅2 |
| 作者单位 | 徐州市红十字血液中心 2.徐州医科大学附属医院 |
| 通信邮箱 | zhangshuai@xzhmu.edu.cn; |
| 中图分类号 | R440 |
| 卷期页码 | 2026, 2(04): 165-168 |
| 发布时间 | 2026-07-15 |
| 出版时间 | 2026-07-15 |
| 引用信息 | [1]钱露,张帅.核酸检测质量监测指标评价与无效结果成因分析[J].疾病预防与控制,2026,2(04):165-168. |
| 全文地址 | 在知网查看该文(kns.cnki.net) |
| 数据抓取时间 | 2026-09-22T12:15:55 |